Fri, May 17, 2024
[ 12:00 AM ] - WOPRAI
Wed, May 15, 2024
[ 12:00 AM ] - WOPRAI
Thu, May 9, 2024
[ 12:00 AM ] - WOPRAI
Tue, March 12, 2024
[ 12:00 AM ] - WOPRAI
Wed, February 28, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, February 23, 2024
[ 12:00 AM ] - WOPRAI
Wed, February 14, 2024
[ 12:00 AM ] - WOPRAI
Wed, January 3, 2024
[ 12:00 AM ] - WOPRAI
Tue, January 2, 2024
[ 12:00 AM ] - WOPRAI
Fri, December 29, 2023
[ 12:00 AM ] - WOPRAI
Mon, November 6, 2023
[ 12:00 AM ] - WOPRAI
Fri, October 27, 2023
[ 12:00 AM ] - WOPRAI
Thu, October 26, 2023
[ 12:00 AM ] - WOPRAI
Tue, September 26, 2023
[ 12:00 AM ] - WOPRAI
Mon, September 25, 2023
[ 12:00 AM ] - WOPRAI
Wed, June 14, 2023
Mon, June 12, 2023
[ 12:00 AM ] - WOPRAI
Wed, May 10, 2023
[ 12:00 AM ] - WOPRAI
Thu, April 27, 2023
[ 12:00 AM ] - WOPRAI
Fri, April 14, 2023
[ 12:00 AM ] - WOPRAI
Tue, April 11, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, March 17, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, March 13, 2023
Tue, February 28, 2023
[ 12:00 AM ] - WOPRAI
Wed, December 21, 2022
[ 12:00 AM ] - WOPRAI
Tue, November 22, 2022
Uy Ear Maintained (SRPT) at Strong Buy with Increased Target to $179 on, May 17th, 2024
Uy Ear of Mizuho, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $145 to $179 on, May 17th, 2024.
Uy has made no other calls on SRPT in the last 4 months.
There are 11 other peers that have a rating on SRPT. Out of the 11 peers that are also analyzing SRPT, 2 agree with Uy's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Kristen Kluska of "Cantor Fitzgerald" Reiterated at Hold and Held Target at $128 on, Thursday, May 2nd, 2024
- Gavin Clark-Gartner of "Evercore ISI Group" Maintained at Hold with Increased Target to $138 on, Tuesday, February 20th, 2024
These are the ratings of the 9 analyists that currently disagree with Uy
- Hartaj Singh of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $180 on, Tuesday, May 14th, 2024
- Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $175 on, Friday, May 3rd, 2024
- Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $166 on, Thursday, May 2nd, 2024
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $167 on, Friday, March 1st, 2024
- David Hoang of "Citigroup" Maintained at Strong Buy with Increased Target to $172 on, Thursday, February 29th, 2024
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $157 on, Thursday, February 29th, 2024
- Gena Wang of "Barclays" Maintained at Buy with Increased Target to $185 on, Thursday, February 29th, 2024
- Andreas Argyrides of "Wedbush" Reiterated at Buy and Held Target at $224 on, Tuesday, February 20th, 2024
- Kostas Biliouris of "BMO Capital" Initiated at Buy and Held Target at $170 on, Wednesday, January 31st, 2024
Contributing Sources